IL140499A0 - Nalladase inhibitors useful as pharmaceutical compounds and compositions - Google Patents
Nalladase inhibitors useful as pharmaceutical compounds and compositionsInfo
- Publication number
- IL140499A0 IL140499A0 IL14049999A IL14049999A IL140499A0 IL 140499 A0 IL140499 A0 IL 140499A0 IL 14049999 A IL14049999 A IL 14049999A IL 14049999 A IL14049999 A IL 14049999A IL 140499 A0 IL140499 A0 IL 140499A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- nalladase
- pharmaceutical compounds
- inhibitors useful
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/17—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/18—Dithiocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/36—Esters of dithiocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- C07C329/12—Dithiocarbonic acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/18—Esters of dithiocarbamic acids
- C07C333/20—Esters of dithiocarbamic acids having nitrogen atoms of dithiocarbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11018698A | 1998-07-06 | 1998-07-06 | |
US09/110,262 US6395718B1 (en) | 1998-07-06 | 1998-07-06 | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US09/228,391 US6265609B1 (en) | 1998-07-06 | 1999-01-12 | Thio-substituted pentanedioic acid derivatives |
PCT/US1999/015128 WO2000001668A2 (en) | 1998-07-06 | 1999-07-02 | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
IL140499A0 true IL140499A0 (en) | 2002-02-10 |
Family
ID=27380804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14049999A IL140499A0 (en) | 1998-07-06 | 1999-07-02 | Nalladase inhibitors useful as pharmaceutical compounds and compositions |
Country Status (21)
Country | Link |
---|---|
US (2) | US6458775B1 (xx) |
EP (2) | EP1093453B1 (xx) |
JP (1) | JP4503836B2 (xx) |
KR (1) | KR100672965B1 (xx) |
CN (1) | CN1314882A (xx) |
AT (1) | ATE305449T1 (xx) |
AU (1) | AU770258B2 (xx) |
BR (1) | BR9912516A (xx) |
CA (1) | CA2337797C (xx) |
CZ (1) | CZ200113A3 (xx) |
DE (1) | DE69927502T2 (xx) |
ES (1) | ES2251204T3 (xx) |
HK (1) | HK1036617A1 (xx) |
HU (1) | HUP0103382A3 (xx) |
IL (1) | IL140499A0 (xx) |
MX (1) | MXPA01000144A (xx) |
NO (1) | NO20010052L (xx) |
NZ (1) | NZ508978A (xx) |
PL (1) | PL346762A1 (xx) |
TR (1) | TR200100025T2 (xx) |
WO (1) | WO2000001668A2 (xx) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6228888B1 (en) * | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
CA2410889A1 (en) | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating retinal disorders and glaucoma |
AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
WO2001091738A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
EP1353903A2 (en) | 2001-01-17 | 2003-10-22 | Guilford Pharmaceuticals Inc. | Thiol-based naaladase inhibitors |
WO2002092553A1 (en) * | 2001-05-11 | 2002-11-21 | Guilford Pharmaceuticals Inc. | Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
JP4292471B2 (ja) * | 2001-05-30 | 2009-07-08 | エーザイ コーポレーション オブ ノース アメリカ | チオールアルキル安息香酸誘導体 |
AU2002356844C1 (en) | 2001-10-23 | 2010-03-04 | Amgen Fremont Inc. | PSMA antibodies and protein multimers |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
AU2002357003A1 (en) * | 2001-12-28 | 2003-07-24 | Guilford Pharmaceuticals Inc. | Indoles as naaladase inhibitors |
EP1988088A1 (en) * | 2003-03-03 | 2008-11-05 | Guilford Pharmaceuticals Inc. | Thiolactones |
US20040186081A1 (en) * | 2003-03-03 | 2004-09-23 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating opioid tolerance |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5018886B2 (xx) * | 1971-10-13 | 1975-07-02 | ||
SU548609A1 (ru) * | 1975-04-19 | 1977-02-28 | Предприятие П/Я Г-4236 | СОЛИ БИС-(у-СУЛЬФОПРОПИОНАТПРОПИЛ-ИЛИ СУЛЬФОИЗОБУТИРАТПРОПИЛ)-ПОЛИДИМЕТИЛ-СИЛОКСАНА, ОБЛАДАЮЩИЕ ПОВЕРХНОСТНО-АКТИВНЫМИСВОЙСТВАМИ1Изобретение относитс к новым химическим соединени м, а именно к сол м бис-(у-сульфо-0нропионатпропил- или сульфонзобутиратпро- пил)-нолидиметилснлоксана общей формулыСНз СНзСН, \КОз5СН2СН(р.)С(о)о(СН2)з-31-0-[81-о]-81-((:Н5,)зО(о)ССН(к)СН2бОзМ\<т\сн, ш,сн3где R = H, СНз; M = Na, К, NH4;m = 4, 8, 12, 16, обладающим поверхност- 5 но-активными свойствами.Соли бис-(•у-сульфопроиионатпропил- н сульфоизобутиратиропил) - нолидиметнлсилок- сана указанной формулы, обладающие повы- щенной поверхностной активностью могут 10 примен тьс в качестве эффективных поверх- ностио-активных веществ (ПАВ).Р1звестны ПАВ на основе кремнийорганнче- ских сульфоэфиров ^[1], сульфатов [2] или сульфонатов [3], снижающие поверхностное 15 нат жение воды до 20—30 дин/см.Наиболее близкими по технической сущности к описываемым соединени м вл ютс Na, К или NH4 соли 1,3-бис-(сульфопропионатал- кил- или сульфоизобутираталкил-1,1,3,3-тетра- 20 метилдисилоксана [4].Однако указанные соединени имеют недостаточную активность на границах фаз: вода — воздух (снижают поверхностное нат жение с 72,5 до 25—30 дин/см) и вода — кремний — органическа жидкость (снижают межфазовое нат жение с 47 до 6—14 дин/см).Целью изобретени вл етс синтез соединений, обладающих высокой эффективностью действи в качестве ПАВ.Дл этого используемые в качестве ПАВ соли бис- (i'-сульфопропионатнроиил- или сульфоизобутнратпропил) - иолидиметилсил- оксана содержат в своем составе удлиненную силоксановую день.Введение солей указанной формулы в концентраци х 1-10~з — 5-10~2 моль/л приводит к резкому снижению поверхностного нат л<е- ни воды (с 72,5 до 17 дин/см) и межфазного нат жени на границе вода — полиднметил- силоксан (с 47,7 до 4,3 дин/см).Соли бис-(у-сульфоироинонатпропнл- и сульфонзобутиратиропил) - полидиметилсил- |
US4151172A (en) | 1977-08-11 | 1979-04-24 | E. R. Squibb & Sons, Inc. | Phosphonoacyl prolines and related compounds |
EP0002219B1 (de) * | 1977-12-02 | 1980-12-10 | Troponwerke GmbH & Co. KG | Arzneimittel mit schwefelhaltigen Estern und Verfahren zu ihrer Herstellung |
US4316896A (en) | 1978-09-07 | 1982-02-23 | Merck & Co., Inc. | Aminoacid derivatives as antihypertensives |
US4168267A (en) | 1978-10-23 | 1979-09-18 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl prolines |
US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4374131A (en) | 1981-04-27 | 1983-02-15 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinyl-alkanoyl compounds |
US4716155A (en) | 1981-12-24 | 1987-12-29 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and hypotensive use thereof |
US4555506A (en) | 1981-12-24 | 1985-11-26 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and use as hypotensives |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
US5162512A (en) | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4560680A (en) | 1982-03-15 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
US4452791A (en) | 1982-03-15 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
US4448772A (en) | 1982-04-22 | 1984-05-15 | E. R. Squibb & Sons, Inc. | Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension |
US4560681A (en) | 1982-04-22 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension |
US4468519A (en) | 1982-06-14 | 1984-08-28 | E. R. Squibb & Sons, Inc. | Esters of phosphinylalkanoyl substituted prolines |
US4703043A (en) | 1982-06-23 | 1987-10-27 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
US4452790A (en) | 1982-06-23 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
US4616005A (en) | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
US4567166A (en) | 1982-07-14 | 1986-01-28 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension |
US4444765A (en) | 1982-07-14 | 1984-04-24 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension |
US4547324A (en) | 1982-07-29 | 1985-10-15 | Stauffer Chemical Company | Method for preparation of N-phosphonomethylglycine |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
FR2590674B1 (fr) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | Nouveaux reactifs de diagnostic |
US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5099063A (en) | 1986-11-05 | 1992-03-24 | Merck & Co., Inc. | Certain phosphinic acid derivatives having antibacterial activity |
US5143908A (en) | 1986-11-05 | 1992-09-01 | Merck & Co., Inc. | Antibacterial agents and potentiators of carbapenem antibiotics |
US4715994A (en) | 1986-11-05 | 1987-12-29 | Merck & Co., Inc. | Novel antibacterial agents and potentiators of carbapenem antibiotics |
ZW23187A1 (en) | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
US4758584A (en) | 1987-02-05 | 1988-07-19 | Ciba-Geigy Corporation | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups |
US5010103A (en) * | 1987-06-04 | 1991-04-23 | The Research Foundation Of State University Of N.Y. | Compositions and methods comprising 2-mercaptomethylglutaric acid derivatives |
US4927966A (en) * | 1987-06-04 | 1990-05-22 | The Research Foundation Of State University Of New York | 2-mercaptomethylglutaric acid derivatives |
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US5041644A (en) | 1987-07-06 | 1991-08-20 | Merck & Co., Inc. | Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid |
JPS6413097A (en) | 1987-07-06 | 1989-01-17 | Mitsubishi Chem Ind | Phosphonic acid derivative |
US4849525A (en) | 1987-09-21 | 1989-07-18 | E. R. Squibb & Sons, Inc. | Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides |
US4918064A (en) | 1987-10-21 | 1990-04-17 | G. D. Searle & Co. | Phenyl glycines for use in reducing neurotoxic injury |
US5871472A (en) | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
US4937183A (en) | 1988-02-03 | 1990-06-26 | Cytogen Corporation | Method for the preparation of antibody-fragment conjugates |
US5047227A (en) | 1988-02-08 | 1991-09-10 | Cytogen Corporation | Novel and improved antibodies for site specific attachment of compounds |
US5030732A (en) | 1988-03-03 | 1991-07-09 | Merck & Co., Inc. | Aminoethylphosphinic acid derivatives |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
EP0347840B1 (en) | 1988-06-23 | 1995-12-27 | Banyu Pharmaceutical Co., Ltd. | Phosphinic acid derivates |
US4962097A (en) | 1988-10-28 | 1990-10-09 | Merck & Co., Inc. | Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors |
US5145990A (en) | 1988-10-28 | 1992-09-08 | Merck & Co., Inc. | Phosphorous containing dhp enzyme inhibitors |
US5147867A (en) | 1988-10-28 | 1992-09-15 | Merck & Co., Inc. | Phosphorus containing enzyme inhibitors |
US5196510A (en) | 1988-12-29 | 1993-03-23 | Cytogen Corporation | Molecular recognition units |
US4994446A (en) | 1989-01-03 | 1991-02-19 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Drug system |
CA2023099A1 (en) | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
US5136080A (en) | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5336689A (en) | 1990-03-02 | 1994-08-09 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
JP2632754B2 (ja) | 1991-05-21 | 1997-07-23 | 塩野義製薬株式会社 | 脳内グルタミン酸遊離抑制剤 |
DE4141928A1 (de) | 1991-12-19 | 1993-06-24 | Boehringer Mannheim Gmbh | Neue phosphonobernsteinsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
USH1312H (en) | 1992-05-28 | 1994-05-03 | Cytogen Corporation | Method for the preparation of gyk-dtpa |
US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
EP1757694A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5449761A (en) | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
US5495042A (en) | 1993-11-04 | 1996-02-27 | Cytogen Corporation | Non-alkaline purification of aminophosphonic acids |
US5500420A (en) | 1993-12-20 | 1996-03-19 | Cornell Research Foundation, Inc. | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia |
US5508273A (en) | 1993-12-30 | 1996-04-16 | Ortho Pharmaceutical Corporation | Substituted phosphonic acids and derivatives useful in treating bone wasting diseases |
GB9403909D0 (en) | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
US5698402A (en) | 1995-02-23 | 1997-12-16 | Dianon Systems, Inc. | Methods for diagnosing benign prostatic hyperplasia |
DE69635801T2 (de) | 1995-02-24 | 2006-11-02 | Sloan-Kettering Institute For Cancer Research | Prostataspezifisches membranes antigen und seine anwendungen |
US5795877A (en) * | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
RU2218179C2 (ru) * | 1996-06-17 | 2003-12-10 | Гилфорд Фармасьютикалз Инк. | СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы |
US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
US5977090A (en) * | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
US6017903A (en) * | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US6025344A (en) * | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
ID18382A (id) * | 1996-09-27 | 1998-04-02 | Guilford Pharm Inc | Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase |
US6265609B1 (en) * | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6228888B1 (en) * | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
-
1999
- 1999-07-02 CN CN99810206A patent/CN1314882A/zh active Pending
- 1999-07-02 DE DE69927502T patent/DE69927502T2/de not_active Revoked
- 1999-07-02 KR KR1020017000232A patent/KR100672965B1/ko not_active IP Right Cessation
- 1999-07-02 CZ CZ200113A patent/CZ200113A3/cs unknown
- 1999-07-02 US US09/346,711 patent/US6458775B1/en not_active Expired - Fee Related
- 1999-07-02 JP JP2000558073A patent/JP4503836B2/ja not_active Expired - Fee Related
- 1999-07-02 TR TR2001/00025T patent/TR200100025T2/xx unknown
- 1999-07-02 BR BR9912516-1A patent/BR9912516A/pt not_active IP Right Cessation
- 1999-07-02 NZ NZ508978A patent/NZ508978A/en not_active IP Right Cessation
- 1999-07-02 IL IL14049999A patent/IL140499A0/xx active IP Right Grant
- 1999-07-02 WO PCT/US1999/015128 patent/WO2000001668A2/en active IP Right Grant
- 1999-07-02 HU HU0103382A patent/HUP0103382A3/hu unknown
- 1999-07-02 MX MXPA01000144A patent/MXPA01000144A/es not_active IP Right Cessation
- 1999-07-02 AT AT99932229T patent/ATE305449T1/de not_active IP Right Cessation
- 1999-07-02 AU AU48583/99A patent/AU770258B2/en not_active Ceased
- 1999-07-02 ES ES99932229T patent/ES2251204T3/es not_active Expired - Lifetime
- 1999-07-02 EP EP99932229A patent/EP1093453B1/en not_active Revoked
- 1999-07-02 EP EP05010637A patent/EP1571141A2/en not_active Withdrawn
- 1999-07-02 PL PL99346762A patent/PL346762A1/xx not_active Application Discontinuation
- 1999-07-02 CA CA002337797A patent/CA2337797C/en not_active Expired - Fee Related
-
2001
- 2001-01-04 NO NO20010052A patent/NO20010052L/no not_active Application Discontinuation
- 2001-10-19 HK HK01107357A patent/HK1036617A1/xx not_active IP Right Cessation
-
2002
- 2002-06-10 US US10/164,553 patent/US20030083374A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030083374A1 (en) | 2003-05-01 |
AU770258B2 (en) | 2004-02-19 |
CZ200113A3 (cs) | 2001-08-15 |
CN1314882A (zh) | 2001-09-26 |
US6458775B1 (en) | 2002-10-01 |
EP1093453A1 (en) | 2001-04-25 |
NO20010052L (no) | 2001-03-02 |
TR200100025T2 (tr) | 2001-12-21 |
WO2000001668A2 (en) | 2000-01-13 |
NZ508978A (en) | 2005-03-24 |
ES2251204T3 (es) | 2006-04-16 |
AU4858399A (en) | 2000-01-24 |
ATE305449T1 (de) | 2005-10-15 |
JP4503836B2 (ja) | 2010-07-14 |
WO2000001668A3 (en) | 2000-09-21 |
BR9912516A (pt) | 2001-09-18 |
CA2337797A1 (en) | 2000-01-13 |
MXPA01000144A (es) | 2002-10-17 |
CA2337797C (en) | 2009-04-14 |
NO20010052D0 (no) | 2001-01-04 |
DE69927502D1 (de) | 2005-11-03 |
HUP0103382A3 (en) | 2002-12-28 |
JP2002519408A (ja) | 2002-07-02 |
EP1571141A2 (en) | 2005-09-07 |
HK1036617A1 (en) | 2002-01-11 |
KR100672965B1 (ko) | 2007-02-28 |
DE69927502T2 (de) | 2006-07-06 |
PL346762A1 (en) | 2002-02-25 |
HUP0103382A2 (en) | 2002-06-29 |
KR20010099586A (ko) | 2001-11-09 |
EP1093453B1 (en) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1036617A1 (en) | Naaladase inhibitors useful as pharmaceutical compounds and compositions | |
EP1039887A4 (en) | PROCESS FOR THE TREATMENT OF NEURO AND NEPHROTOXICITIES AND THERAPEUTIC TOXICITIES WITH AMINOTHIOL COMPOUNDS | |
ATE222889T1 (de) | Hydroxamsäure-derivate | |
IT1276041B1 (it) | Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose | |
DE69903618D1 (en) | Phosphinsäure-derivate | |
ZA933768B (en) | Novel phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism metabolism. | |
IL118426A (en) | Pharmaceutical composition containing 1,3- bis-triazolyl-2-propanol derivative for treating cancer tumors or viruses | |
WO2002057222A3 (en) | Thiol-based naaladase inhibitors | |
EP1716856A3 (en) | The treatment of acne | |
WO2001034596A3 (en) | Pyrrolecarbonylimino derivatives as naaladase inhibitors | |
ES2136252T3 (es) | Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. | |
IL125776A (en) | Use of a cimicifuga racemosa extract for the manufacture of a drug for treating estrogen-dependent tumors | |
WO2001030335A3 (en) | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease | |
AU5170499A (en) | Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis | |
GEP20032914B (en) | Derivatives of 1,3,4-Oxadiazolone | |
CA2296560A1 (en) | Amino acid derivatives useful to treat stroke | |
DE60018186D1 (de) | Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie | |
HU9401656D0 (en) | Pharmaceutical composition for treating tumours, containing creatine phosphate or phospho-enol-pyruvic acid | |
AU3308099A (en) | Method for the treatment of pain, including chronic and female specific pain | |
ZA200102727B (en) | Method of treating sickle cell disease or thalassemia. | |
WO2002089848A3 (en) | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes | |
AU5857899A (en) | Use of tgf-beta inhibitors for treating cerebral disorders | |
MY114109A (en) | The use of bioassimilable boron compounds | |
UA36385A (uk) | Спосіб лікування генералізованого пародонтиту | |
CA2112501A1 (fr) | Composition therapeutique nouvelle remediant aux desordres survenant dans la sphere orl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |